Official Louisiana State Websites use .la.gov 
Secure .gov websites use HTTPS 
| Item Number | State Plan Title | Summary of Change | Date Posted | Comment Period Closed | Document Links |
|---|---|---|---|---|---|
| SPA-2024-01 | ICF/IID Reimbursement Methodology | The purpose of this SPA is to amend the provisions governing the reimbursement methodology for Intermediate Care Facilities for Individuals with Intellectual Disabilities (ICF/IID), by continuing the $12 add‐on to private (non-state) owned ICF/IID for increased costs related to retaining and hiring direct care staff, through June 30, 2025. | 5/8/24 | 6/8/24 | Attachment 4.19-D, Page 26 |
| SPA-2023-06 | Pharmacy Benefits Management Program | The purpose of this SPA is to amend the provisions governing reimbursement in the Pharmacy Benefits Management program in order to increase the professional dispensing fee to $11.81 per prescription. | 5/31/23 | 6/29/23 | Attachment 4.19-B Item 12a Page 1 |
| SPA-2023-05 | American Rescue Plan Act COVID-19 Vaccine, Vaccine Administration, and Treatment | The purpose of this SPA is to demonstrate compliance with the American Rescue Plan Act provisions that require states to cover COVID-19 vaccines, vaccine administration, and treatment. | 5/25/23 | 6/1/23 | 7.4-A Vaccine and Vaccine Administration at Section 1905(a)(4)(F) of the Social Security Act 7.4-C COVID-19 Treatment at Section 1905(a)(4)(F) of the Social Security Act |
Medicaid State Plan Amendments
Louisiana’s Medicaid State Plan is an agreement between the state and the Federal government describing how Louisiana administers its Medicaid and children’s health insurance programs (CHIP). State Plan Amendments (SPA) are requests from Louisiana to the Centers for Medicare & Medicaid Services (CMS) to make a change to the Louisiana Medicaid program’s policies or operational approach, make corrections, or update the state plan with new information. For information about current State Plan amendment submissions, click here.
Below are SPAs Louisiana will send to CMS for review and approval beginning August 1, 2019.